Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604
about
Action and therapeutic potential of oxyntomodulinResponse to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:25A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic TissuesIncretins: their physiology and application in the treatment of diabetes mellitus.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
P2860
Q27025870-1EED6CF9-2BD5-4775-8EC9-F50E9E30024FQ28679307-90AF0A5D-D51D-44F9-AE50-5C5726514E7EQ35138670-F44B0D60-1EC9-426B-9254-B23F50D89CB0Q36665328-DB1AA404-67A7-44B2-849F-BCB40630B209Q38225693-2B47F0D7-71B3-4BCB-86A8-474866BFE6B9Q38255715-23ED3159-AE41-49DD-B630-6BEC84A2A6B8Q38601929-D1D2964E-22CD-443C-A6B0-9429E73F3F6AQ52780711-993E39FE-4D31-4EBF-9E4E-119583337E0C
P2860
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comment on: Butler et al. Mark ...... rs. Diabetes 2013;62:2595-2604
@en
Comment on: Butler et al. Mark ...... s. Diabetes 2013;62:2595-2604.
@nl
type
label
Comment on: Butler et al. Mark ...... rs. Diabetes 2013;62:2595-2604
@en
Comment on: Butler et al. Mark ...... s. Diabetes 2013;62:2595-2604.
@nl
prefLabel
Comment on: Butler et al. Mark ...... rs. Diabetes 2013;62:2595-2604
@en
Comment on: Butler et al. Mark ...... s. Diabetes 2013;62:2595-2604.
@nl
P2093
P2860
P356
P1433
P1476
Comment on: Butler et al. Mark ...... rs. Diabetes 2013;62:2595-2604
@en
P2093
David E Moller
David M Kendall
P2860
P356
10.2337/DB13-0690
P407
P577
2013-10-01T00:00:00Z